Thymulin (FTS): immune system hormone that helps T cells grow up
A natural hormone made by the thymus gland that helps immune cells mature; requires zinc to work; experimental, not yet an approved drug.
- Class
- Thymic peptide — zinc-dependent immunomodulatory nonapeptide
- Status
- No approved therapeutic indication in any major regulatory jurisdiction
- Best-supported effect
- Endogenous role in T-cell differentiation and maturation (animal / in vitro; established immunology); zinc supplementation restoring endogenous thymulin activity in zinc-deficient populations (human RCT evidence — zinc intervention, not exogenous peptide administration)
- Main caveat
- Best-evidenced clinical action for supporting thymulin biology is correcting zinc deficiency, not injecting synthetic thymulin. Human evidence for exogenous synthetic thymulin is thin: decades-old investigational work in small immunodeficient cohorts; no completed controlled human efficacy trial
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Thymic peptide — zinc-dependent immunomodulatory nonapeptide
Evidence tier: Animal-only evidence
Status: No approved therapeutic indication in any major regulatory jurisdiction
Best-supported effect: Endogenous role in T-cell differentiation and maturation (established immunology; animal and in vitro); zinc supplementation restores endogenous thymulin activity in zinc-deficient populations (human RCT evidence — zinc intervention, not exogenous peptide administration)
Main caveat: The best-evidenced clinical action for supporting thymulin biology is correcting zinc deficiency, not injecting synthetic thymulin. Human evidence for exogenous synthetic thymulin administration is thin: decades-old investigational work in small immunodeficient cohorts with no controlled efficacy trials. The endogenous biology is well-characterized; the exogenous therapeutic use is not
What this is
Thymulin is a nine-amino-acid (nonapeptide) hormone produced by thymic epithelial cells. It requires a tightly bound zinc ion to be biologically active — the peptide without zinc (apothymulin) is essentially inert as a receptor ligand. Thymulin plays a central role in T-cell differentiation and maturation, and its circulating levels decline as the thymus involutes with age.
Originally called Facteur Thymique Sérique (FTS), the peptide was isolated and characterized beginning in the 1970s by Jean-François Bach, Mireille Dardenne, and colleagues at the Necker Hospital and INSERM in Paris. Across the 1970s through 1990s, the Bach/Dardenne group established thymulin's role in CD4/CD8 T-cell lineage commitment, its zinc dependence, its circadian regulation by melatonin, and its bidirectional relationship with the hypothalamic-pituitary-thymic axis. The zinc-dependence observation also explained a longstanding clinical pattern: zinc deficiency produces immune phenotypes resembling thymic atrophy, and zinc repletion restores functional thymulin activity in deficient individuals.
Despite this scientific depth, thymulin has never been developed into an approved therapeutic. More recent preclinical research — using both the parent nonapeptide and thymulin-related analogs, particularly the peptide analogue of thymulin (PAT) — has explored analgesic, anti-inflammatory, and disease-model applications in animal systems. Human translational work has not followed.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | Observational / biomarker | Multiple human clinical trials and RCTs have characterized endogenous thymulin biology: zinc supplementation restores functional thymulin levels in zinc-deficient populations (elderly, IBD, pediatric malnutrition, AIDS patients); melatonin drives nocturnal thymulin elevation in humans; serum thymulin is measurably reduced in human zinc deficiency. These are endogenous biomarker studies and zinc intervention trials — not exogenous synthetic thymulin administration trials. Source describes historical small investigational studies in immunodeficient cohorts as the only human exposure evidence for the synthetic peptide; individual trial records are not extracted |
| Animal | Moderate | T-cell maturation and differentiation; anti-inflammatory effects in rodent models of inflammation and sepsis; analgesic effects in pain behavior models; protection in experimental MS (EAE), streptozotocin-induced type 1 diabetes, and allergic asthma models. Both parent nonapeptide and PAT analog studied across models |
| In vitro | Moderate | Zinc-binding site characterization; receptor binding on T-cell precursors; protein kinase C activation; intracellular calcium dynamics in thymocytes; cytokine modulation; antibody generation tools |
| Computational | None identified | No computational or structure-prediction data present in source |
| Mechanism | Strong (endogenous biology) | Zinc-thymulin complex binds high-affinity surface receptors on T-cell precursors, activating PKC signaling; role in CD4/CD8 lineage commitment and cytokine regulation is well-established across decades of immunology. Translation of this mechanism to exogenous parenteral synthetic thymulin in adult humans has not been confirmed in controlled studies |
Source-concentration and replication note: The foundational characterization of thymulin and much of the preclinical evidence originates from the Bach/Dardenne research group at INSERM Paris. Human data is from zinc supplementation intervention studies and observational biomarker work — not from controlled trials of exogenous synthetic thymulin. Animal evidence for pain and inflammation involves both the parent nonapeptide and PAT (a distinct analog molecule); evidence for the parent peptide specifically and evidence for the analog should not be conflated.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Zinc-thymulin complex is required for biological activity; zinc-free apothymulin is inactive | Supported (in vitro / biochemical) | In vitro | High — foundational biochemistry; established across zinc-binding and receptor assays |
| Zinc supplementation restores endogenous thymulin activity in zinc-deficient populations | Supported (human RCTs — zinc intervention) | Human | High — multiple RCTs in elderly, IBD, AIDS, and pediatric malnutrition populations; this is evidence for zinc supplementation restoring endogenous thymulin, not for exogenous synthetic thymulin administration |
| Endogenous T-cell differentiation and maturation role | Supported (animal / in vitro) | Animal | High — well-established immunology; animal models and in vitro systems |
| Anti-inflammatory and analgesic effects of exogenous thymulin | Supported (preclinical) | Animal | Medium — rodent models of inflammation, pain, sepsis; some evidence uses PAT analog rather than parent nonapeptide; no controlled human evidence for exogenous synthetic thymulin |
| Human efficacy for any indication via exogenous synthetic thymulin injection | Not established | Human | High confidence in verdict — published literature explicitly states human evidence is thin, limited to decades-old small investigational studies in immunodeficient cohorts; no completed controlled human efficacy trial is extractable from source |
| Immune restoration in aging via injected synthetic thymulin | Not established | Human | High confidence in verdict — endogenous thymulin decline with aging is documented; published literature explicitly identifies "injecting thymulin restores a youthful immune system" as a myth; no controlled human efficacy trial present |
| Thymulin is biologically equivalent to Thymosin Alpha-1 | Contradicted | Animal / human | High — distinct peptides with different structures, mechanisms, and clinical histories; published literature explicitly names this as a myth |
Experimental exposure
This section reports exposure used in animal experiments and historical investigational human context. It does not establish human dosing.
| Context | System | Experimental exposure | Duration | Endpoint | Limitation |
|---|---|---|---|---|---|
| Rodent pain, inflammation, MS, diabetes, and sepsis models | Rats / mice | Microgram-range doses by intraperitoneal or subcutaneous routes; per-study doses not individually extracted | Days to weeks per study | Pain behavior scores, inflammatory markers, cytokine levels, pathological markers in disease models | Rodent models; route and dose not validated in humans; some studies use PAT analog alongside parent peptide |
| Historical investigational human cohorts | Small immunodeficient patient populations | Microgram-scale parenteral doses (historical); exact regimens not individually extracted in source | Short windows; specific durations not extracted | Immune parameter shifts | Decades-old; uncontrolled; selected populations; not applicable to current use contexts; no pharmacokinetic data from current research-chemical preparations |
| Human zinc supplementation trials (endogenous thymulin biomarker context) | Elderly adults, IBD patients, pediatric malnutrition, AIDS patients | Oral zinc supplementation; exact doses not individually extracted per trial | Variable per trial | Serum thymulin activity restoration; immune parameters | These are zinc intervention trials — they measure restoration of endogenous thymulin activity as a biomarker endpoint; they are not exogenous synthetic thymulin administration trials and do not establish dosing for synthetic peptide |
Preclinical safety signals
| Signal | System | Notes |
|---|---|---|
| Generally described as well-tolerated in short animal studies | Rodent | Source-bundle general statement; detailed per-study animal toxicology not individually extracted |
| Biological inactivity without zinc | All systems | Zinc-free apothymulin is inactive; zinc status of the recipient and zinc-loading state of the synthetic preparation are pharmacologically relevant variables; no controlled study has characterized this difference in humans |
| Research-chemical supply quality | Not a biological signal | Purity, peptide identity, and endotoxin contamination vary substantially across unregulated suppliers; not independently characterized for end users |
| Long-term safety of chronic exogenous administration | Not established | No chronic human safety data present in source; long-term animal toxicology not individually extracted |
Source-described theoretical cautions (no controlled safety program attached): Active autoimmune disease — thymulin's T-cell maturation role makes immune effects in autoimmune populations uncharted; organ transplantation requiring immunosuppression — interference with immunosuppression regimens is unstudied; pregnancy and breastfeeding — no reproductive safety data; pediatric populations — no studies of synthetic exogenous thymulin in children; known hypersensitivity to peptide therapeutics or excipients in research-chemical preparations of unverified composition; use of unverified research-chemical material in any clinical context — purity and endotoxin status are not assured outside regulated supply chains.
No human adverse event table is present in the attached source. Human safety data for exogenous synthetic thymulin administration in controlled conditions has not been individually extracted in this card.
Regulatory status
| Region / body | Status | Notes |
|---|---|---|
| US (FDA) | Not approved | No FDA-approved indication; no legitimate prescription pathway identified in source; synthetic thymulin in the research-chemical market is labeled "not for human consumption" and is not authorized for therapeutic use |
| EU | No marketing authorization (per available sources) | Per available sources, no EU marketing authorization; not independently refreshed in this card |
| UK | No marketing authorization (per available sources) | per available sources |
| Canada | No marketing authorization (per available sources) | per available sources |
| Australia | No marketing authorization (per available sources) | per available sources |
| Eastern Europe | Investigational / limited historical use | Source notes a longer history of investigational and limited-use status for thymic peptides in some Eastern European countries; no current major-market approval identified |
| WADA | Not specifically named; likely falls under S0 | Per available sources, thymulin is not specifically named on the WADA Prohibited List; source notes it would fall under S0 (substances not approved by any governmental health authority for human therapeutic use) for athletes using exogenous synthetic thymulin; status is per available sources and not independently verified against the current WADA list |
Zinc supplementation is an over-the-counter dietary supplement and is not WADA-prohibited.
Mechanism
Thymulin binds to high-affinity surface receptors on T-cell precursors in the thymus, promoting their differentiation into mature CD4+ and CD8+ T-cells. Biological activity is strictly dependent on the peptide carrying a bound zinc ion; without zinc, the apoprotein does not activate the receptor pathway. The zinc-thymulin complex activates protein kinase C (PKC) signaling and influences intracellular calcium dynamics in thymocytes. Downstream effects include modulation of cytokine production, enhancement of natural killer cell activity, and influence on the hypothalamic-pituitary-adrenal axis through the neuroendocrine-thymic axis.
Endogenous thymulin levels follow a circadian pattern with nocturnal peaks linked to melatonin signaling. This circadian regulation is established in both animal and human biomarker studies.
In preclinical pain and inflammation models, thymulin and related analogs — particularly the peptide analogue of thymulin (PAT) — have shown analgesic and anti-inflammatory effects attributed to modulation of spinal inflammatory signaling pathways and neuroinflammation attenuation. The relative contributions of the parent nonapeptide and PAT in these models have not been cleanly separated across studies.
Target confidence is verified for endogenous thymulin biology. Translation of the receptor-level mechanism to parenterally administered synthetic thymulin in adult humans has not been established in controlled studies.
Chemistry
| Field | Value |
|---|---|
| Common name | Thymulin |
| Other names | Facteur Thymique Sérique (FTS), FTS, Zinc-Thymulin, Serum Thymic Factor |
| Sequence | pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (9 residues; N-terminal pyroglutamate) |
| Length | 9 amino acids (nonapeptide) |
| Topology | Linear |
| Key feature | Requires zinc cofactor for biological activity; zinc-free apothymulin is biologically inactive |
| Molecular weight | ~857 Da (apoprotein; approximate; does not include bound zinc) |
| Formula | Not individually extracted from source |
| CAS | Not individually extracted from source |
| Sequence confidence | Needs review — sequence is from established thymulin literature; available literature does not provide a machine-readable sequence string; needs independent verification against primary chemistry source |
The zinc-binding requirement is a pharmacologically defining property. The zinc status of the recipient and the zinc-loading state of any synthetic preparation are both relevant variables for any exogenous administration context — and this has not been characterized in controlled human studies.
Open questions
- Central translational gap: Whether adding exogenous synthetic thymulin to a zinc-replete patient produces any clinical benefit beyond what zinc supplementation alone achieves has never been tested in a controlled human study. This is the foundational unanswered question for any therapeutic use of the synthetic peptide.
- Human pharmacokinetics of current research-chemical preparations: Absorption, distribution, half-life, and tissue uptake have not been characterized in humans for synthetic thymulin as currently sold. Dosing rationale is entirely speculative in the absence of PK data.
- Zinc-status interaction in exogenous administration: Injecting synthetic thymulin into zinc-deficient and zinc-replete patients would be expected to produce different pharmacological outcomes; no controlled study has characterized this difference.
- Parent nonapeptide vs PAT contributions: Preclinical evidence for analgesic and anti-inflammatory effects involves both the parent thymulin nonapeptide and PAT, a distinct synthetic analog. The extent to which observations in animal models are attributable to each molecule separately is not clearly resolved across published research literature.
- Long-term safety of chronic exogenous administration: No chronic human safety data is present in this card. The immune consequences of sustained exogenous thymulin in adults are unknown.
- Research-chemical supply quality: Purity, peptide identity, and endotoxin contamination vary substantially across research-chemical thymulin suppliers and have not been independently characterized for end users.
- Human translation of preclinical disease-model findings: Promising animal results in MS, asthma, and type 1 diabetes models have not been followed by published human controlled trials. Translation potential is unknown.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does zinc make thymulin active by forcing it into a specific shape that a zinc-free but pre-shaped version might also achieve?
The zinc requirement makes thymulin unstable and hard to develop as a drug. If a rigidified version could work without zinc, it could be manufactured reliably, stored more easily, and potentially given orally, making it a realistic medicine for immune deficiency and aging.
Could chemists make a circular version of thymulin that stays in the active shape on its own, bypassing the need for zinc entirely?
The zinc requirement makes thymulin fragile and difficult to deliver as a drug. A self-stable ring version would be far easier to manufacture and store, could survive longer in the bloodstream, and might even work as a pill, transforming an interesting research compound into a real medicine for immune deficiency.
Since thymulin needs zinc to work, is getting more zinc into thymic cells a more efficient way to boost thymulin activity than injecting synthetic thymulin?
Zinc supplements are safe, cheap, and widely available. If simply ensuring adequate zinc restores the body's own thymulin activity in older adults, it would be an immediate, low-cost public health intervention to reduce infection risk and potentially improve vaccine responses in the elderly.
Does thymulin boost immunity indirectly by first signaling through the pituitary gland rather than acting directly on immune cells?
If thymulin works through the brain-hormone system, it would open entirely new ways to deliver it, including nasal sprays that reach the brain. It would also connect immune decline in aging to the broader hormonal changes of aging, suggesting that treating one might treat the other.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8413631916046143 | openfold3-mlx |
| ranking score | 0.9048908352851868 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.426 | global PDE — lower = better |
| disorder | 0.112 | fraction disordered |
| chain pair ipTM (A, B) | 0.841 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | — |
| hardware | — |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | — |
| diffusion samples | 1 |
| runtime | 80s |
| predicted by | mlx@peptide |
| predicted at | 2026-05-03 |
▸citationbibtex
@peptide{pep10917,
sequence = {EAKSQGGSN},
target = {immune},
author = {peptidemodel},
year = {2026},
status = {computed}
}